항정신성 약물 시장 규모, 점유율, 성장 분석 : 약제 유형별, 용도별, 치료 클래스별, 질환별, 유통경로별, 지역별 - 업계 예측(2026-2033년)

Global Psychotropic Drugs Market size was valued at USD 24.8 Billion in 2024 and is poised to grow from USD 25.84 Billion in 2025 to USD 35.91 Billion by 2033, growing at a CAGR of 4.2% during the forecast period (2026-2033).

The global psychotropic drugs market is experiencing significant growth due to heightened awareness of mental health issues, alongside rising anxiety and depression rates. Enhanced access to healthcare services contributes to this trend, while advancements in drug development technologies further drive market expansion. Societal acceptance of psychiatric treatment is also on the rise, bolstered by government support for mental health initiatives and improved diagnostic capabilities. Additionally, emerging economies and increasing discretionary incomes worldwide are facilitating greater utilization of psychotropic medications. Collectively, these factors are creating a robust demand for psychotropic drugs, positioning the market for continued expansion and innovation in addressing mental health needs globally.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Psychotropic Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Psychotropic Drugs Market Segments Analysis

Global Psychotropic Drugs Market is segmented by Drug Type, Application, Therapeutic Class, Disease, Distribution Channel and region. Based on Drug Type, the market is segmented into Aripiprazole, Brexipiprazole, Olanzapine, Peliperidone Palmitate, Clozapine, Quetiapine, Chlorpromazine, Risperidone, Paroxetine, Thioridazine, Fluvoxamine and Other Drug Types. Based on Application, the market is segmented into Anti-Psychotics, Anti-Anxiety, Mood Stabilizers, Antidepressants, Stimulants, Hypnotics, Antiepileptic Drugs and Other Applications. Based on Therapeutic Class, the market is segmented into First Generation, Second Generation and Third Generation. Based on Disease, the market is segmented into Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia and Other Diseases. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Psychotropic Drugs Market

The Global Psychotropic Drugs market is significantly propelled by the increasing awareness around mental health, largely fueled by public information campaigns and the support of high-profile celebrities. This growing recognition of mental health issues has led to higher rates of diagnosis and subsequently greater demand for treatment options. Additionally, supportive government policies and international initiatives aimed at mental health improvement have further facilitated access to various psychotropic medications such as antidepressants, anxiolytics, and antipsychotics. Workplace wellness programs also contribute to this trend, particularly in urban environments where people experience heightened stress, thus amplifying the need for effective mental health solutions.

Restraints in the Global Psychotropic Drugs Market

The Global Psychotropic Drugs market faces significant restraints due to the rigorous safety and efficacy evaluations mandated by regulatory authorities, which can prolong the path to market entry. The testing process for psychiatric drugs is complex, often requiring intricate clinical trials that involve subjective diagnoses, contributing to high development costs. Furthermore, the ongoing requirements for post-marketing surveillance add financial burdens, particularly the need to monitor the safety of medications, such as anti-depressants concerning suicide risk. These challenges create obstacles for smaller pharmaceutical companies that may struggle to manage the financial demands associated with bringing psychotropic drugs to market effectively.

Market Trends of the Global Psychotropic Drugs Market

The Global Psychotropic Drugs market is increasingly embracing the paradigm of personalized medicine and biomarker-driven therapies, which prioritize tailored treatment approaches over traditional one-size-fits-all methods. Innovations in genetic testing and pharmacogenomics enable practitioners to select optimal treatments for mental health disorders, significantly enhancing efficacy while minimizing the guesswork involved in prescribing medications. Companies such as COMPASS Pathways are pioneering the development of psychedelic-based therapies, capturing substantial venture capital investments and forging strategic partnerships within the healthcare ecosystem. This shift toward precision pharmacotherapy is expected to reshape the landscape of mental health treatment, leading to improved patient outcomes and market growth.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Psychotropic Drugs Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Aripiprazole
• Brexipiprazole
• Olanzapine
• Peliperidone Palmitate
• Clozapine
• Quetiapine
• Chlorpromazine
• Risperidone
• Paroxetine
• Thioridazine
• Fluvoxamine
• Other Drug Types

Global Psychotropic Drugs Market Size by Application & CAGR (2026-2033)

• Market Overview
• Anti-Psychotics
• Anti-Anxiety
• Mood Stabilizers
• Antidepressants
• Stimulants
• Hypnotics
• Antiepileptic Drugs
• Other Applications

Global Psychotropic Drugs Market Size by Therapeutic Class & CAGR (2026-2033)

• Market Overview
• First Generation
• Second Generation
• Third Generation

Global Psychotropic Drugs Market Size by Disease & CAGR (2026-2033)

• Market Overview
• Schizophrenia
• Bipolar Disorder
• Unipolar Depression
• Dementia
• Other Diseases

Global Psychotropic Drugs Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Psychotropic Drugs Market Size & CAGR (2026-2033)

• North America (Drug Type, Application, Therapeutic Class, Disease, Distribution Channel)
  • US
  • Canada
• Europe (Drug Type, Application, Therapeutic Class, Disease, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Application, Therapeutic Class, Disease, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Application, Therapeutic Class, Disease, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Application, Therapeutic Class, Disease, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca Plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Holdings Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (GSK) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (BMS) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Pharmaceuticals (J&J Subsidiary) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jazz Pharmaceuticals plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurocrine Biosciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations